Navigation Links
Pharmaceutical advances offer new options for health outcomes
Date:5/20/2013

Orlando, FL (May 20, 2013) Research presented at Digestive Disease Week (DDW) explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatitis C.

An international study holds promising results for patients suffering from IBS-D. In the phase II study, researchers found that the drug ibodutant significantly improved symptoms in more than 50 percent of the individuals treated.

"While there's been a lot of progress in medicines for IBS with constipation, we haven't seen the same in IBS with diarrhea," said Jan Tack, MD, professor and director of the division of gastroenterology and internal medicine at Leuven University in Belgium. "Up to this point, we haven't been able to provide a pharmaceutical option for this patient group that successfully manages the pain associated with the condition."

IBS is an extremely common condition, affecting an estimated 10 percent of adults. Funded by Menarini, the double-blind, multinational study recruited 559 patients with IBS-D who were randomized and treated with 1, 3 or 10 mg of ibodutant or a placebo. Patients took an oral tablet once daily for eight consecutive weeks. Researchers found that 10 mg was the most effective dose and that it worked best for females.

"These are exciting findings that could bring a lot of relief to many patients," said Dr. Tack said. "We're looking forward to moving into phase III to confirm our findings with a much larger sample of patients."

New therapy for patients with hepatitis C examined

New research suggests that an investigational therapy for patients with hepatitis C can achieve high response rates in a wide range of patients, even those who respond poorly to current treatments. The study examined the safety and efficacy of interferon-free regimens, including three direct-acting antiviral drugs with and without ribavirin, for 12 or 24 weeks, in patients with chronic hepatitis C who were either treatment-nave or had previously failed standard treatment with peginterferon and ribavirin.

In the phase II study, researchers found that the treatment regimens achieved high sustained virologic response (SVR) rates, an efficacy measure of a hepatitis C treatment, in non-cirrhotic patients with HCV genotype-1 (GT 1). SVR was achieved by 98.7 percent of treatment-nave patients and 93.3 percent of prior nonresponders after 12 weeks of treatment with three direct-acting agents with ribavirin.

"Hepatitis C genotype 1 is the most common type of hepatitis in the U.S., and many of these patients are still quite difficult to treat with current interferon-based therapies," said Frederick Nunes, MD, clinical associate professor of medicine at Penn Medicine. "This includes specific populations such as African Americans and patients with high body mass or pre-diabetes. These results suggest that highly effective regimens like this one may overcome that difficulty, without the need for interferon."


'/>"/>

Contact: Aimee Frank
newsroom@gastro.org
407-685-4030
Digestive Disease Week
Source:Eurekalert

Related medicine news :

1. Active Pharmaceutical Ingredients (API) Market in Europe Will Reach $38,255.67 Million By 2017- Pricing and Reimbursement Initiatives Supporting Generic Drug Growth
2. Cloud Computing in Pharmaceutical Research and Development - Virtualization of Data through the Cloud Optimizes Next-Generation DNA Sequencing and Clinical Trials Data
3. Aeolus Pharmaceuticals To Present At Taglich Brothers 10th Annual Small Cap Equity Conference
4. TraceLink Leads Pharmaceutical Track and Trace, Big Data and Cloud-based Supply Networks Discussion at LogiPharma Europe Conference
5. Corporate Whistle Blower Center Now Urges Pharmaceutical Insiders Or Physicians To Become A Whistleblower If They Can Prove A Drug Maker Was Knowingly Involved In Bribery
6. Pharmaceutical advertising down but not out
7. Pharmaceutical companies: An $84 million marketing effort in the District of Columbia
8. Survey shows medical students have frequent interactions with pharmaceutical companies
9. Radiopharmaceuticals Market - New Industry Research Report Published by Transparency Market Research
10. Sewage lagoons remove most -- but not all -- pharmaceuticals
11. Pharmaceutical Manufacturing in China Industry Research Report – Now Available from IBISWorld
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... OMI Industries, a worldwide ... a distribution partnership with Byers Scientific & Manufacturing , a leading designer, ... the agreement, OMI Industries formulated a special version of Ecosorb® for Byers Scientific ...
(Date:1/24/2017)... ... ... This Saturday, January 28, the BCFA presents more than 20 local performances including Chinese ... Yifan Zhou, Mara McClain & Sarah Nordlund Dennis. Local chefs and restaurants provide a ... Chinese games, crafts & more. Festivities begin at 11:00 am and end at 2:30 ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the ... everyone and particularly good news for prostate cancer patients: incidents of cancer is down ... to the report the cancer death rate has dropped from its peak of 215.1 ...
(Date:1/24/2017)... ... January 24, 2017 , ... Today, Taza ... latest award-winning bottles, designed specifically to optimize the drinking experience for K-Cup coffee, ... renowned for introducing the world’s first untouched bottled water purposed exclusively for creating ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Choosing ... like finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. ... Dr. Judith Coats and Dr. David Coats. In September of 1983, they flew ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)...  In a major study released this weekend ... 1 ( http://www.multivu.com/players/English/7899551-nephrocheck-test-acute-kidney-injury-outcomes/ ), Astute ... identified patients at high risk of Acute Kidney ... randomized control trial led by Alexander Zarbock ... institution,s standard of care or a treatment per ...
(Date:1/24/2017)... Jan. 24, 2017 When tragedy strikes, victims often can,t ... what conditions they have, and who back home is wondering about ... ones informed about the safety of their family and friends, while ... victims in times of crisis. ... If you find yourself or your family in one ...
(Date:1/24/2017)... 2017 Market Research Future has a half cooked research ... market for Plastic Surgery & Integumentary System is growing rapidly and ... forecasted period. Market Highlights ... Global Plastic Surgery & Integumentary System Market has ... market will reach high growth figures and thriving in the coming ...
Breaking Medicine Technology: